In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line
2022Bulletin of the National Research Centre/Bulletin of the National Research CenterJournalOpen access
10.1186/s42269-021-00690-zFull text59 citations